Artiva Biotherapeutics said the FDA granted RMAT status to AlloNK plus rituximab for refractory autoimmune cases, a move that could speed clinical development.

BWB News TV • 2026-08-06 20:11 UTC • By Billy Odell Tucker-Robinson

$Artiva Biotherapeutics said the FDA granted RMAT status to AlloNK plus rituximab for refractory autoimmune cases, a move that could speed clinical development.$

Artiva Biotherapeutics said the FDA granted RMAT status to AlloNK plus rituximab for refractory autoimmune cases, a move that could speed clinical development. The company also cited new EULAR 2026 data in its Q2 update.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly